12:27:21 EDT Wed 04 Aug 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Peter Lacey Increases His Investment in Hemostemix Inc.

2021-06-21 22:02 ET - News Release

Calgary, Alberta--(Newsfile Corp. - June 21, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO) ("Hemostemix" or the "Company") announced today that, further to its June 11, 2021 news release and pursuant to the closing of the offering of debenture units of the Company ("Debenture Units"), Peter Lacey, a director and Chair of Hemostemix, acquired the 2,500 Debenture Units. Each Debenture Unit consisted of a $1,000 principal amount debenture (each, a "Debenture") and 2,500 common share purchase warrants ("Debenture Warrants"). The ‎principal amount of the Debentures may be convertible, only at the option of the Company (and not at the option of ‎the holder), into common shares of the Company ("Common Shares") of the at a price of $0.40 per Common Share. Each Debenture Warrant entitles the holder to acquire one Common Share at a price of $0.55 per Common Share until June 10, 2023, subject to accelerated expiry provisions. Prior to the offering, Mr. Lacey held ‎4,491,891‎ Common Shares, or approximately 7.80% of the total issued and outstanding Common Shares. Mr. Lacey also held 4,500,000 common share purchase warrants and 555,000 stock options. Mr. Lacey now controls ‎ ‎4,491,891‎ Common Shares, or approximately 7.80% of the total issued and outstanding Common Shares, the Debenture in the principal amount of $2,500,000, ‎10,750,000 common share purchase warrants (including the Debenture Warrants) and 555,000 stock options. Assuming the conversion of the Debenture and the exercise of the common share purchase warrants (including the Debenture Warrants) and the stock options, Mr. Lacey would own or control ‎22,046,891 Common Shares, or approximately 29.35% of the total issued and outstanding Common Shares. The acquisition of ‎the Debenture Units by Mr. Lacey was made for investment purposes. Mr. Lacey may increase or ‎decrease his investment in Hemostemix depending on market conditions or any ‎other relevant factors. The ‎head office address for Hemostemix is Suite 1150, 707 - 7th Avenue SW, Calgary, Alberta T2P 3H6. The address for Mr. Lacey is 38501 Range ‎Road 272‎, Red Deer, Alberta T4P 0X6. ‎

ABOUT HEMOSTEMIX

Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 500 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup" which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years. The Company owns 91 patents across five patent families. For more information, please visit www.hemostemix.com.

Contact: Thomas Smeenk, President, CEO & Co-Founder
TSmeenk@Hemostemix.com Tel. 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/88254

© 2021 Canjex Publishing Ltd. All rights reserved.